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The cyclic AMP-dependent protein kinase (PKA), which activates prosurvival signaling proteins, has been implicated in the
expression of long-term potentiation and hippocampal long-term memory. It has come to light that H89 commonly known as
the PKA inhibitor have diverse roles in the nervous system that are unrelated to its role as a PKA inhibitor. We have investigated
the role of H89 in ischemic and reperfusion injury. First, we examined the expression of postsynaptic density protein 95 (PSD95),
microtubule-associated protein 2 (MAP2), and synaptophysin in mouse brain after middle cerebral artery occlusion injury. Next,
we examined the role of H89 pretreatment on the expression of brain-derived neurotrophic factor (BDNF), PSD95, MAP2, and
the apoptosis regulators Bcl2 and cleaved caspase-3 in cultured neuroblastoma cells exposed to hypoxia and reperfusion injury. In
addition, we investigated the alteration of AKT activation in H89 pretreated neuroblastoma cells under hypoxia and reperfusion
injury. The data suggest that H89 may contribute to brain recovery after ischemic stroke by regulating neuronal death and proteins
related to synaptic plasticity.
1. Introduction
Protein kinase A (PKA) [1] acts to phosphorylate other
proteins, regulating them in a reversiblemanner.When cyclic
adenosine monophosphate (cAMP) binds to the subunits of
PKA, they undergo a conformational change that promotes
phosphorylation [2]. PKA is implicated also in neural health.
It stimulates neurite outgrowth in neurons and neuronal cell
lines [3, 4] and promotes axon regeneration in vivo [5, 6].
cAMP/PKA signaling affects long-term synaptic plasticity
and long-term memory [7].
Many studies that evaluate the role of PKA, which
include smooth muscle cells [8, 9], neuronal tissue [10,
11], and epithelial cells [12, 13], have relied on the iso-
quinoline derivative N-[2-p-bromocinnamylamino-ethyl]-5-
isoquinolinesulfonamide (H89), an inhibitor of PKA. H89
has an inhibition constant (𝐾
𝑖
) of 0.05mM in its inhibition
of PKA [14, 15]. However, effects of H89 that are unrelated
to its inhibition have been observed. In a kinase study, at
a concentration of 10 𝜇M, H89 inhibited the activity of the
protein kinases Rho-associated kinase- (ROCK-) II, MSK1
and the ribosomal protein S6 kinase 𝛽-1 (S6K1) far more
potently than it inhibited PKA itself [16]. In addition, H89
10 𝜇M maintains the neurite outgrowth of neuroblastoma
cells [17]. There are several reports that H89 reduced Ca2+
uptake into the sarcoplasmic reticulum by attenuating the
Ca2+-ATPase’s [18] affinity for calcium [19]. At 20𝜇M, H89
prevented the glucose-induced increase in cytosolic calcium
in pancreatic islets and attenuated the release of calcium
in a differentiated 𝛽-cell line. In a study of expression of
myelin basic protein in oligodendrocytes, H89 is involved in
the phosphorylation of extracellular-signal–regulated kinase
1 and 2 (ERK 1 and 2) phosphorylation in response to insulin-
like growth factor-1 [20] and it lowered potassium current
through voltage-gated channels in rat myocytes [21].
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Of particular interest is the H89 inhibition of S6K1, noted
above. S6K1 is a downstream target of the mammalian target
of rapamycin (mTOR) protein, which regulates the autophagy
pathway [22] and is a mechanism target for regulation of cell
size [23]. Several researchers have questioned the role of PKA
in autophagy, since the studies rely at least in part on the
selectivity of H89, which they consider uncertain [24, 25].
The second issue involves the action of H89 itself. Clearly, it
has physiological effects unrelated to PKA. We have elected
to examine those effects and chose to focus on H89’s role in
neural health, especially ischemic stroke.
Cerebral ischemia leads to neuronal death and synaptic
dysfunction, resulting in cognitive decline [26–29]. Under-
standing the pathogenesis after ischemic stroke should
inform medical care and maximize recovery. In the present
study, we investigated the role of H89 in many aspects of
nervous system function. Specifically, we examined its role in
the expression of brain-derived neurotrophic factor (BDNF)
in the development of neurites to axons [30–32], learning and
memory [33], synaptic plasticity [34], the expression of B-cell
lymphoma 2 (Bcl2) [35, 36] as it relates to neuronal death,
the expression of synaptophysin [37], postsynaptic density
protein 95 (PSD-95) [38, 39] as it relates to synaptic plas-
ticity, and the expression of microtubule-associated protein
2 (MAP2). The latter interacts with actin filaments, shown
to be necessary for neurite outgrowth [40–43] in a middle
cerebral artery occlusion (MCAO) animal model and in an in
vitro study. In present study, we suggest that H89 may confer
protection from brain damage following cerebral ischemia.
2. Materials and Methods
2.1. Animal Model. Male C57BL/6 mice (Orient, GyeongGi-
Do, Korea) that were eight-to-twelve weeks old were used
in this study. Hypoxia followed by reperfusion (H/R) was
imposed by subjecting mice to transient focal cerebral
ischemia by intraluminal middle cerebral artery blockade
with a nylon suture, as previously described [44]. After
60min of MCAO, blood flow was restored by withdrawing
the suture and regional cerebral blood flow was monitored
with a laser Doppler flow meter (Transonic Systems, Inc.,
Ithaca, NY, USA). All animal procedures and experiments
were performed in accordance with the Guide to the Care
and Use of Laboratory Animals and were approved by the
Association for Assessment and Accreditation of Laboratory
Animal Care. All procedures were done at room temperature
unless indicated otherwise. We used 5 rats in each group for
study. Each measurement included 3 repeats per animal.
2.2. Immunohistochemistry. Frozen brain sections were cut
into 5𝜇msections andmounted on clean glass slides (Thermo
Scientific, Waltham, MA, USA), air-dried, and fixed in cold
acetone for 10min at −20∘C. The slides were washed in
Tris-buffered saline (TBS; 20 nM Tris (pH 7.2), 150mM
NaCl), incubated with 0.3% H
2
O
2
in methanol to quench
endogenous peroxidase activity, and washed three times
with distilled water, and the sections were blocked with
10% normal rabbit serum. Additional frozen brain sections
(20𝜇m) were fixed in ice-cold acetone for 20min. To block
nonspecific labeling, sections were incubated in 5% bovine
serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA)
in 0.1% phosphate-buffered saline (PBS) for 30min before
addition of primary and secondary antibodies. Primary
antibodies for PSD-95 (1 : 100, Millipore, Massachusetts, MA,
USA), synaptophysin (1 : 100, Millipore, Massachusetts, MA,
USA), and MAP2 (1 : 100, Abcam, Cambridge, MA, USA)
were applied to the samples for 24 h at 4∘C; then the samples
were incubated with the appropriate florescence secondary
antibody (1 : 100, Invitrogen, Carlsbad, CA, USA) for 90min,
washed three times for 10min in PBS with Tween-20 (PBST),
and incubated with rhodamine-conjugated sheep anti-rabbit
or fluorescein isothiocyanate- (FITC-) conjugated sheep anti-
mouse secondary antibody (both diluted to 1 : 200 with
5% BSA fraction V in 0.1% PBST) for 2 h in the dark.
This was followed by three washes in PBS and incubation
in 1 𝜇g/mL 4󸀠,6-diamidino-2-phenylindole (DAPI; Sigma-
Aldrich, St. Louis, MO, USA) for counterstaining. Tissues
were then visualized under a confocalmicroscope (Zeiss LSM
700, Carl Zeiss, Thornwood, NY, USA).
2.3. Cell Culture. Neuro2A (N2A) cells purchased from
ATCC biotechnology (ATCC, Manassas, VA, USA) were
derived from mouse neuroblastoma. The cells exhibited
properties of neuronal stem cells and were capable of differ-
entiating into neuron-like cells in the presence of retinoic acid
(RA). Undifferentiated N2A cells were cultured in Dulbecco’s
modified eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS; Gibco, Grand Island, NY, USA) and
100 𝜇g/mLpenicillin-streptomycin (Gibco,Grand Island,NY,
USA). N2A cells were passaged at least twice and then plated
at 5 × 104 cells/mL in DMEM supplemented with 10% FBS
for 24 h, after which the medium was changed to DMEM
supplemented with 2% FBS and 20 𝜇MRA for differentiation.
Cultures were maintained in a humidified atmosphere of 5%
CO
2
at 37∘C.The medium was changed every two days [45].
2.4. Hypoxia and Reperfusion (H/R) and H89 Treatment.
Confluent cells were transferred to an anaerobic chamber
(Forma Scientific, OH, USA, O
2
tension = 0.1%). They
were washed three times with PBS and the culture medium
was replaced with deoxygenated, glucose-free balanced salt
solution and incubated for 4 h. Following H/R injury, cells
were incubated for 18 h under normal growth conditions
[46]. H89 (10 𝜇M, Sigma-Aldrich, St. Louis, MO, USA) was
treated in the N2A cells at 2 h before H/R injury. In present
study, we used the 10𝜇M concentration of H89, considering
previous researches regarding other functions except from
PKA inhibitor[17–19, 47, 48].
2.5. Neurite Length Measurement. To determine the length
of their neurites, the cells were fixed for 20min in 3.7%
formaldehyde. Neurite formation was defined as an out-
growth from the cell body that was longer than the diameter
of the cell body. N2A cells in three randomly selected fields
(30–100 cells per field) were measured using ImageJ software
(ImageJ, Madison, WI, USA) [49]. At least 30 cells per
treatment were scored [50].
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Figure 1: Immunochemical image for confirmation reduced synaptophysin expression in MCAO mouse brain. Immunochemical images
showed that synaptophysin-positive cells (red) were decreased as expressed in MCAO mouse cortex. In addition, immunochemical images
showed that MAP2- (considered as the neuron specific microtubule protein) positive cells (green) were strongly decreased in MCAOmouse
cortex compared to the normal group. We used 5 rats in each groups for study. Each measurement included 3 repeats per animal. Scale
bar = 100𝜇m, synaptophysin: red, MAP2: green, 4󸀠, 6-diamidino-2-phenylindole (DAPI): blue, normal: normal control group, and MCAO:
reperfusion 24 hr after MCAO injury.
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Figure 2: Immunochemical image for confirmation reduced PSD-95 expression in MCAO mouse brain. Immunochemical images showed
that PSD-95- (as the post synaptic density protein) positive cells (red) were decreased as expressed in MCAO mouse cortex. Postsynaptic
proteins were hardly observed inMCAOmouse brain cortex, whereas the normal cortexwas observed evidently.We used 5 rats in each groups
for study. Each measurement included 3 repeats per animal. Scale bar = 100𝜇m, PSD-95: red, MAP2: green, 4󸀠,6-diamidino-2-phenylindole
(DAPI): blue, normal: normal control group, and MCAO: reperfusion 24 hr after MCAO injury.
2.6. Reverse Transcription PCR (RT-PCR). To examine the
expression of BDNF, Bcl2, and MAP2 in N2A cells after
H/R injury, RT-PCR was performed. Briefly, samples were
lysed with TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
and total RNA was extracted according to the manu-
facturer’s protocol. Complementary DNA synthesis from
mRNA and sample normalization was performed. PCR
was performed using the following thermal cycling condi-
tions: 10min at 95∘C, 35 cycles of denaturing at 95∘C for
15 sec, annealing for 30 sec at 70∘C, elongation at 72∘C for
30 sec, final extension for 10min at 72∘C, and maintenance
at 4∘C. PCR was performed using the following primers
(5󸀠 to 3󸀠); BDNF (F): AGT GAT GAC CAT CCT TTT
CCT TAC, (R): CCT CAA ATG TGT CAT CCA AGG
A, Bcl2 (F): AAG CTG TCA CAG AGG GGC TA, (R):
CAGGCTGGAAGGAGAAGA TG,MAP2 (F): TGA AGA
ATG GCA GAT GAA C, (R): AGA AGG AGG CAG ATT
AGC, GAPDH (F): GGCATGGACTGTGGTCATGAG, (R):
TGCACCACCAACTGCTTAGC. PCR products were elec-
trophoresed in 1.5% agarose gels and stained with ethidium
bromide.
2.7. Western Blot Analysis. After H/R injury, cells were
washed rapidly with ice-cold PBS, scraped, and collected.
Cell pellets were lysed with ice-cold RIPA buffer (Sigma-
Aldrich, St. Louis, MO, USA). The lysates were centrifuged
at 13,200 rpm for 1 h at 4∘C to produce whole-cell extracts.
Protein was quantified with the bicinchoninic acid (BCA)
method (Pierce biotechnology, Rockford, IL, USA). Protein
(20𝜇g) was separated on a 10% SDS–polyacrylamide (PAGE)
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Figure 3:Themeasurement of neurite outgrowth in Neuro2A cells. (a)The graph of neurite outgrowth length (𝜇m) in all groups.The neurite
length significantly decreases in N2A cells against hypoxia reperfusion injury. Data are expressed as mean ± S.E.M. Significant intergroup
differenceswere determined by one-way analysis of variance (ANOVA) followedbyBonferroni post hocmultiple-comparison test.Differences
were considered significant at ∗𝑃 < 0.05. (b) The image using bright field microscope in the normal group shows well developed neurite of
N2A cells. (c) The image using bright field microscope in hypoxia reperfusion group shows shorter neurite outgrowth of N2A cells than the
normal group. (d)The image using bright field microscope in H89 group shows well developed neurite of N2A cells compared to the hypoxia
reperfusion group. Each experiment included 3 repeats per condition. H89 protected N2A cells against the neurite damage under H/R injury.
Normal: the normal control group, H/R: 4 hr hypoxia and 18 hr reperfusion injury group, and H89: 2 hr PKA inhibitor H89 treatment group
before 4 hr hypoxia and 18 hr reperfusion injury.
gel and transferred onto a polyvinylidene difluoride (PVDF)
membrane. After blocking with 5% BSA (in TBS/Tween
[TBS-T]) for 1 h, immunoblots were incubated overnight at
4∘C with primary antibodies specific for Bcl2 (1 : 2000, Milli-
pore, Massachusetts, MA, USA), cleaved caspase-3 (1 : 2000,
Santa Cruz, Santa Cruz, CA, USA), PSD-95 (1 : 2000, Mil-
lipore, Massachusetts, MA, USA), AKT (1 : 2000, Cell sig-
naling, Danvers, MA, USA), p-AKT (1 : 2000, Cell signaling,
Danvers, MA, USA), or 𝛽-actin (1 : 2000, Santa Cruz, Santa
Cruz, CA, USA). Next, blots were incubated with horseradish
peroxidase- (HRP-) linked anti-mouse and anti-rabbit IgG
antibodies purchased fromAbcam (Abcam, Cambridge,MA,
USA) for 1 h. Enhanced chemiluminescence was performed
by electrochemiluminescence (ECL: Pierce Biotechnology,
Rockford, IL, USA) [51].
2.8. Immunocytochemistry. The expression of BDNF, cleaved
caspase-3, Bcl2, and PSD-95 in N2A cells was confirmed by
immunocytochemistry. Cells in all experimental groups were
washed three times with PBS, fixed with 4% paraformalde-
hyde for 3 h, and then washed with PBS. N2A cells were
permeabilized with 0.025% Triton X-100 and blocked for
1 h with dilution buffer (Invitrogen, Carlsbad, CA, USA).
The following primary antibodies: anti-rabbit BDNF (1 : 500,
Abcam, Cambridge,MA, USA), anti-rabbit cleaved caspase-3
(1 : 500, Santa Cruz, Santa Cruz, CA, USA), anti-rabbit PSD-
95 (1 : 500, Millipore, Massachusetts, MA, USA), anti-mouse
Bcl2 (1 : 500, Millipore, Massachusetts, MA, USA) were pre-
pared in dilution buffer, added to samples, and incubated
for 3 h. Primary antibody was then removed and cells were
washed three times for 3min each with PBS. Later, sam-
ples were incubated with FITC-conjugated goat, anti-rabbit
(1 : 200, Jackson Immunoresearch, PA, USA), or rhodamine-
conjugated donkey, anti-mouse secondary antibodies (1 : 500,
Millipore, Massachusetts, MA, USA) for 2 h. Cells were
washed again three times for 3min eachwith PBS and stained
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with 1 𝜇g/mL DAPI (1 : 100, Sigma-Aldrich, St. Louis, MO,
USA) for 10min at room temperature. Fixed samples were
imaged using a Zeiss LSM 700 confocal microscope (Carl
Zeiss, Thornwood, NY, USA).
2.9. Statistical Analysis. Statistical analyses were carried out
using SPSS 18.0 software (IBM Corp., Armonk, NY, USA).
Data are expressed as mean ± S.E.M. Significant intergroup
differences were determined by one-way analysis of vari-
ance (ANOVA) followed by Bonferroni post hoc multiple-
comparison test. Each experiment included four replicates
per treatment. Differences were considered significant at 𝑃 <
0.05 (∗) or 𝑃 < 0.001 (∗∗).
3. Results
3.1. MCAO Mouse Brain Exhibited Neuronal Death and
Synaptic Plasticity Damage. We performed immunohisto-
chemistry of the brain of H/R injured and control mice, using
antibodies to synaptophysin (Figure 1), PSD-95 (Figure 2),
and MAP2 (Figures 1 and 2). The former two were used as
markers of synaptic plasticity; the latter is considered to be a
neuronal microtubule protein marker.The immunoreactivity
of all three proteins was less in the H/R injured group than
in the control group. These results indicate that cerebral
ischemia suppresses the expression of synaptophysin, PSD-
95, and MAP2 in ischemic brain and that synaptic neuronal
microtubule proteins were damaged by ischemic injury.
3.2. H/R Injury in Neuro2A Cells Inhibited, and H89 Pretreat-
ment Restored, Neurite Outgrowth. Neurite outgrowth of
Neuro2A cells was assessed by measuring neurite length with
ImageJ software (Figure 3). The average length of normal
N2A cells was approximately 65 𝜇m, whereas neurites of
cells subjected to H/R injury were approximately 26 𝜇m long
(Figure 3(a)). Neurites from cells that had been pretreated
with H89 before H/R injury were, on average, approximately
45 𝜇m, or almost twice that of the injured cells that were
not pretreated (Figure 3(a)). Bright-field images showed the
neurite length in all groups (Figures 3(b), 3(c), and 3(d)).The
yellow line in all images permits easy comparison of neurite
lengths.
We also performed RT-PCR (Figure 4) to assess MAP2, a
protein essential to neurite growth [41, 42]. The mRNA level
of MAP2 in H/R injured N2A cells was reduced considerably
compared to the control group (Figure 4). We conclude
that H/R injury leads to reduction of neurite outgrowth,
which can be alleviated by H89 pretreatment.Thus, H89 may
ameliorate the effects of H/R injury.
3.3. Cell Survival Was Increased in H89 Pretreated Neuro2A
Cells after H/R Injury. To confirm whether or not H89
is involved in the neuronal cell death during H/R injury,
we conducted the immunocytochemistry (Figures 5(a) and
5(b)), western blot analysis (Figures 5(c) and 5(d)), and
RT-PCR (Figure 7(b)) using cleaved caspase-3 (as a marker
of mitochondrial cell death) and Bcl2 (as a marker of
anti-apoptosis) antibodies. H/R injured N2A cells were
observed: the reduced Bcl2 immunoreactivity (Figure 5(b)),
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Figure 4:Themeasurement ofMAP2mRNA level in Neuro2A cells
after PKA inhibitor treatment. MAP2 mRNA levels were measured
by using RT-PCR. The H89 group showed higher mRNA levels of
MAP2 compared to the hypoxia reperfusion injury group. Data
were expressed as mean ± S.E.M, and each experiment included 3
repeats per condition. GAPDH was used as a control. Differences
were considered significant at ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001. Normal:
the normal control group, H/R: 4 hr hypoxia and 18 hr reperfusion
injury group, and H89: 2 hr PKA inhibitor H89 treatment group
before 4 hr hypoxia and 18 hr reperfusion injury.
the decreased Bcl2 mRNA level (Figure 7(b)), the attenu-
ated Bcl2 protein level (Figure 5(d)), the increased cleaved
caspase-3 immunoreactivity (Figure 5(a)), and the increased
cleaved caspase-3 protein level (Figure 5(c)). H89 pretreat-
ment before H/R injury group showed the increased Bcl2
expression (Figures 5(b), 5(d), and 7(b)) and the reduced
cleaved caspase-3 expression (Figures 5(a) and 5(c)) com-
pared with the H/R group. These results indicated that the
cell death in N2A cells was attenuated by H89 pretreatment
in spite of hypoxia and reperfusion injury. Thus, we suggest
thatH89may contribute to the neuronal cell survival pathway
under hypoxia and reperfusion injury.
3.4. The Increase of BDNF Expression in Neuro2A Cells
Pretreated with H89 in Hypoxia Reperfusion Injury. We
performed immunocytochemistry analysis (Figure 6) and
RT-PCR (Figure 7(a)) using BDNF as the representative of
neurotrophic factors in N2A cells to examine whether there
was the alteration of neurotrophic factor expression in H89
pretreated N2A cells under hypoxia and reperfusion injury.
We observed evidently lesser immunoreactivity of BDNF
(Figure 6) in the H/R injured N2A cells compared to the
normal control group. However, BDNF- (Figure 6) positive
cells were obviously more expressed in H89 pretreated N2A
cells than the H/R injury group. In addition, the BDNF
mRNA level in N2A cells was higher in H89 pretreated N2A
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Figure 5: The measurement of cleaved caspase-3 and Bcl2 expression in Neuro2A cells after H/R-induced injury. (a) The level of cleaved
caspase-3 was evaluated by immunocytochemistry. This image shows that the expression of cleaved caspase-3 in the H/R group was strongly
increased compared to the normal group. Cleaved caspase-3 expression was attenuated in H89 pretreatment treatment group under H/R-
induced injury. (b)The level of Bcl2 was evaluated by immunocytochemistry. This image shows that the expression of Bcl2 in the H/R group
was increased compared to the normal group. PKA inhibitorH89 pretreatment preserved the expression of Bcl2 in spite of hypoxia reperfusion
injury. (c) Western blotting experiments showed that the relative protein expression of cleaved caspase-3 evidently attenuated in the H89
group compared to the hypoxia reperfusion group. (d) Western blotting experiments showed that the relative protein expression of Bcl2
slightly increased in the H89 group compared to the hypoxia reperfusion group. Data were expressed as mean ± S.E.M, and each experiment
included 4 repeats per condition. Differences were considered significant ∗∗𝑃 < 0.001. Scale bar: 200 𝜇m, cleaved caspase-3: red, Bcl2: green,
4󸀠,6-diamidino-2-phenylindole (DAPI): blue, normal: the normal control group, H/R: 4 hr hypoxia and 18 hr reperfusion injury group, and
H89: 2 hr PKA inhibitor H89 treatment group before 4 hr hypoxia and 18 hr reperfusion injury.
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Figure 6: The measurement of BDNF expression in Neuro2A cells
after H/R-induced injury. The level of BDNF was evaluated by
immunocytochemistry. This image shows that the expression of
BDNF in theH/R groupwas reduced compared to the normal group.
H89 pretreatment increased the expression of BDNF in N2A cells in
spite of hypoxia reperfusion injury. Scale bar: 200 𝜇m, BDNF: green,
4󸀠,6-diamidino-2-phenylindole (DAPI): blue, normal: the normal
control group, H/R: 4 hr hypoxia and 18 hr reperfusion injury group,
and H89: 2 hr PKA inhibitor H89 treatment group before 4 hr
hypoxia and 18 hr reperfusion injury.
cells than the H/R injury group. These results showed that
hypoxia and reperfusion stress suppresses the expression of
BDNF in N2A cells, whereas H89 pretreatment H/R injured
N2A cells considerably did not reduced the expression of
BDNF against H/R injury. Based on these consequences, our
results suggest that neurotrophic factor BDNF’s expression
was not reduced byH89 pretreatment despite ischemic injury.
Thus, H89may contribute to the expression of BDNF in N2A
cells following hypoxia and reperfusion stress.
3.5. The Preservation of PSD-95 Expression in Neuro2A Cells
Pretreated with H89 during Hypoxia Reperfusion Injury. We
performed immunocytochemistry analysis (Figure 8(a)) and
western blot analysis (Figure 8(b)) using PSD-95 antibody in
N2A cells to investigate whether there was the alteration of
synaptic plasticity related proteins in H89 pretreated N2A
cells under hypoxia and reperfusion injury. In addition, we
confirmed evidently decreased immunoreactivity of PSD-95
(Figure 8(a)) in the H/R injured N2A cells compared to the
normal control group. On the other hand, the immunoreac-
tivity of PSD-95 was more increased in H89 pretreated N2A
cells than the H/R injury group (Figure 8(a)). Moreover, the
protein level of PSD-95 (Figure 8(b)) inN2A cells was slightly
higher in H89 pretreated N2A cells than the H/R injury
group. These results indicated that hypoxia and reperfusion
stress reduced the expression of PSD-95 inN2A cells, whereas
H89pretreatmentH/R injuredN2Acells considerably did not
reduce expression of PSD-95 against H/R injury compared
to H/R injured N2A cells. It is possible to extrapolate these
results to suggest that the H/R injury reduced the expression
of PSD-95. Data tend to support the conclusion that H89may
alleviate the synaptic plasticity damage of N2A cells against
ischemic stress.
3.6. The Measurement of Phosphorylation AKT Protein Level
in H89 Pretreated Neuro2A Cells against Hypoxia Reperfusion
Injury. We performed western blot analysis (Figure 9) using
AKT and phosphorylation-AKT (p-AKT) antibody in N2A
cells to investigate the change of AKT phosphorylation in
H89 pretreated N2A cells under hypoxia and reperfusion
injury. The protein level of phosphorylation-AKT (Figure 9)
was evidently increased in H89 pretreated H/R injured N2A
cells than the H/R injury group. This result shows that
H89 considerably promotes the activation of AKT signaling
in N2A cells against H/R injury. Our data supports the
hypothesis that H89 may boost the phosphorylation of AKT
in N2A cells to survive the cells against ischemic stress.
4. Discussion
In cerebral ischemia, the reduction of synaptic dysfunction
and neuronal cell loss are important issues and are impli-
cated in severe pathogenesis such as memory impairment
following ischemic stroke [26–29, 52, 53]. In the search for
a solution, many researchers study the molecules and the
signal pathways that lead to reduced synaptic plasticity and
cell death [54–56]; an example of one is PKA signaling [3–
7]. H89, known as the molecule commonly used to inhibit
PKA action, recently has been reported to have a variety
of functions unrelated to its effect on PKA inhibition [16,
18, 21, 57]. H89 affects ROCK II and, through that effect,
cell morphology [48] and neurite extension [58, 59]. The
data presented here indicate that H89 promotes neurite
outgrowth and protects it after hypoxia stress. MAP2 (known
as the neuron specific cytoskeletal protein) is present during
all stages of neuromorphogenesis [60] and is necessary
for neurite initiation [60–62]. Our MAP2 expression data
support the contention that H89 may also support neurite
outgrowth through MAP2. We speculate that the mainte-
nance of neurite outgrowth after ischemic stroke is central
to the role of H89. Several studies have demonstrated that
H89 induces autophagy in cells independent of PKA signaling
[24, 25] and increases cell survival after inflammation [54,
63]. In the present study, we observed reduced expres-
sion of cleaved caspase-3 and increased expression of Bcl2
following pretreatment with H89, supporting the conclu-
sion that H89 protects against hypoxia injury, specifically,
that it increases neuronal cell survival rate after ischemic
stroke. Neurotrophic molecules regulate synaptic plasticity
of the nervous system [64–66]. Specifically, many researches
demonstrated that BDNF accelerates the axogenesis [30–32],
promotes poststroke plasticity in an in vivo study [32, 67–
71], and contributes to healthy brain function, notably, neu-
ronal survival andmaintenance, neurogenesis, modulation of
dendritic branching and dendritic spinemorphology [72, 73],
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Figure 7:The measurement of BDNF and Bcl2 mRNA level in Neuro2A cells after H/R-induced injury. (a) BDNF and (b) Bcl2 mRNA levels
were measured by using RT-PCR. The H89 pretreatment group showed higher mRNA levels of (a) BDNF and (b) Bcl2 compared to the
hypoxia reperfusion injury group. Data were expressed as mean ± S.E.M, and each experiment included 3 repeats per condition. GAPDH
was used as a control. Differences were considered significant at ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001. Normal: the normal control group, H/R: 4 hr
hypoxia and 18 hr reperfusion injury group, H89: 2 hr PKA inhibitor H89 treatment group before 4 hr hypoxia and 18 hr reperfusion injury.
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Figure 8: The measurement of PSD-95 expression in Neuro2A cells after H/R-induced injury. The level of PSD-95 was evaluated by
immunocytochemistry. This image shows that the expression of PSD-95 in the H/R group was decreased compared to the normal group.
PKA inhibitor H89 pretreatment increased the expression of PSD-95 in spite of hypoxia reperfusion injury. (b)Western blotting experiments
showed that the relative protein expression of PSD-95 slightly increased in theH89 group compared to the hypoxia reperfusion group. 𝛽-actin
was used as an internal control. Data were expressed as mean ± S.E.M, and each experiment included 4 repeats per condition. Differences
were considered significant at ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001. Scale bar: 200 𝜇m, PSD-95: green, 4󸀠, 6-diamidino-2-phenylindole (DAPI): blue,
normal: the normal control group, H/R: 4 hr hypoxia and 18 hr reperfusion injury group, and H89: 2 hr PKA inhibitor H89 treatment group
before 4 hr hypoxia and 18 hr reperfusion injury.
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Figure 9: The measurement of AKT phosphorylation in Neuro2A
cell against H/R injury. Western blotting experiments showed that
the relative protein level of phosphorylation-AKT (p-AKT)/AKT
significantlywas increased in theH89 pretreatment group compared
to the hypoxia and reperfusion group. 𝛽-actin was used as an
internal control. Data were expressed as mean ± S.E.M, and each
experiment included 4 repeats per condition. Differences were
considered significant at ∗∗𝑃 < 0.001. Normal: the normal control
group, H/R: 4 hr hypoxia and 18 hr reperfusion injury group, H89:
2 hr PKA inhibitor H89 treatment group before 4 hr hypoxia and
18 hr reperfusion injury, and p-AKT: phosphorylation-AKT.
and development of neuronal connections required for learn-
ing and memory [74–76]. BDNF, through phosphorylation
of its TrkB receptor, activates a neuron-specific protein,
controls the actin cytoskeleton in dendritic spines [77] and
their regression [78, 79], and promotes the actin polymer-
ization [80]. Inhibition of BDNF synthesis results in smaller
spine heads and impairs long-term potentiation of synaptic
transmission [81, 82]. Moreover, BDNF signaling plays a
crucial role in the development of synapses by controlling the
transport of PSD-95, which is the major scaffolding protein
at mature glutamate synapses [83, 84]. PSD-95 itself and its
interaction with BDNF signaling have been implicated in
diverse brain diseases [85–87]. When localized in postsynap-
tic terminals, PSD-95 has an important role in postsynaptic
function and plasticity [88–90]. The loss of PSD-95 results in
severe cognitive decline due to loss of neurons and synaptic
disruption [91–93]. In addition, synaptophysin as a marker
of the pre-synaptic nerve terminal density is essential for
vesicle fusion and the release of neurotransmitter [94]. The
reduction of synaptophysin has been reported to reduce
synaptic plasticity in the brain [95, 96]. Our results suggest
that H89 may enhance synaptic plasticity by promoting
the BDNF expression in neuronal cells under ischemic brain
injury. Also H89 may be involved in neurite outgrowth by
regulating the preservation of synaptic proteins, such as PSD-
95 and synaptophysin, following ischemic brain damage.
AKT which is activated by phosphatidylinositol 3-kinase
activity [97] has known to promote a cellular protection
after ischemic injury in the brain [98]. Moreover, AKT has
been reported that it mediates anti-apoptosis signalings in
ischemic stroke studies [99, 100]. Some study indicated that
H89 markedly enhances the phosphorylation of AKT [101].
Considering our results, we assume that H89 may contribute
to the survival of neuronal cells against ischemic injury
through the activation of AKT. In present study, although
learning and memory were not assessed in the animal model
used here and we has some limitations to identify the specific
molecular mechanism by H89, we propose that H89 may
ameliorate the pathophysiology following ischemic stroke by
reducing neuronal cell death and involving synaptic plasticity.
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